Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator

Biochemical Pharmacology

Volumn 71, Issue 12, 2006, Pages 1683-1694

  Ahn, G One ^a   Botting, K Jane ^a   Patterson, Adam V ^a   Ware, David C ^a   Tercel, Moana ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

CBI; Co(III) complex; DNA minor groove alkylator; Ionising radiation; Prodrug; Tumour hypoxia

Indexed keywords

ALKYLATING AGENT; BUFFER; CHLOROMETHYLBENZINDOLINE; COBALT COMPLEX; CYCLENAZACHLOROMETHYLBENZINDOLINE COBALT; CYTOCHROME P450 REDUCTASE; FORMIC ACID; GLUCURONIDE; INDOLE DERIVATIVE; PRODRUG; SN 27892; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; BIOASSAY; CELL ACTIVATION; CELL CULTURE; CELL HYPOXIA; CELL STRAIN HT29; CYTOTOXICITY; DNA ALKYLATION; DRUG MONITORING; DRUG POTENCY; ENZYME DEGRADATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROLYSIS; IONIZING RADIATION; IRRADIATION; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOLYSIS;

ALKYLATING AGENTS; AZO COMPOUNDS; BIOTRANSFORMATION; CELL HYPOXIA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COBALT; HT29 CELLS; HUMANS; INDOLES; MASS SPECTROMETRY; PRODRUGS; RADIATION, IONIZING;

EID: 33646497001     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.03.007     Document Type: Article

References (59)

1. Kennedy K.A., Teicher B.A., Rockwell S., and Sartorelli A.C. The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem Pharmacol 29 (1980) 1-8
2. Workman P., and Stratford I.J. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metast Rev 12 (1993) 73-82
3. Denny W.A., Wilson W.R., and Hay M.P. Recent developments in the design of bioreductive drugs. Br J Cancer 74 Suppl. XXVII (1996) S32-S38
4. Brown J.M. The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 59 (1999) 5863-5870
5. Brown J.M., and Wilson W.R. Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer 4 (2004) 437-447
6. Nordsmark M., Overgaard M., and Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41 (1996) 31-39
7. Brizel D.M., Dodge R.K., Clough R.W., and Dewhirst M.W. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53 (1999) 113-117
8. Fyles A.W., Milosevic M., Wong R., Kavanagh M.C., Pintilie M., Sun A., et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48 (1998) 149-156
9. Subarsky P., and Hill R.P. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metast 20 (2003) 237-250
10. Wouters B.G., Weppler S.A., Koritzinsky M., Landuyt W., Nuyts S., Theys J., et al. Hypoxia as a target for combined modality treatments. Eur J Cancer 38 (2002) 240-257
11. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14 (2004) 198-206
12. Rockwell S., Sartorelli A.C., Tomasz M., and Kennedy K.A. Cellular pharmacology of quinone bioreductive alkylating agents. Cancer Metast Rev 12 (1993) 165-176
13. Jaffar M., Naylor M.A., Robertson N., and Stratford I.J. Targeting hypoxia with a new generation of indolequinones. Anticancer Drug Des 13 (1998) 593-609
14. Denny W.A., and Wilson W.R. Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. J Med Chem 29 (1986) 879-887
15. Cole S., Stratford I.J., Fielden E.M., Adams G.E., Leopold W., Elliott W., et al. Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908. Int J Radiat Oncol Biol Phys 22 (1992) 545-548
16. Papadopoulou M.V., and Bloomer W.D. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug. Clin Cancer Res 9 (2003) 5714-5720
17. Denny W.A., and Wilson W.R. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Expert Opin Invest Drugs 9 (2000) 2889-2901
18. Patterson L.H. Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug Metab Rev 34 (2002) 581-592
19. Ware D.C., Palmer B.D., Wilson W.R., and Denny W.A. Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards. J Med Chem 36 (1993) 1839-1846
20. Wilson W.R., Moselen J.W., Cliffe S., Denny W.A., and Ware D.C. Exploiting tumor hypoxia through bioreductive release of diffusible cytotoxins: the cobalt(III)-nitrogen mustard complex SN 24771. Int J Radiat Oncol Biol Phys 29 (1994) 323-327
21. Anderson R.F., Denny W.A., Ware D.C., and Wilson W.R. Pulse radiolysis studies on the hypoxia-selective toxicity of a cobalt-mustard complex. Br J Cancer Suppl. 27 (1996) S48-S51
22. Simic M., and Lilie J. Kinetics of ammonia detachment from reduced cobalt(II) complexes based on conductometric pulse radiolysis. J Am Chem Soc 96 (1973) 291-292
23. Ware D.C., Palmer H.R., Pruijn F.B., Anderson R.F., Brothers P.J., Denny W.A., et al. Bis(dialkyl)dithiocarbamato cobalt(III) complexes of bidentate nitrogen mustards: synthesis, reduction chemistry and biological evaluation as hypoxia-selective cytotoxins. Anticancer Drug Des 13 (1998) 81-103
24. Ware D.C., Brothers P.J., Clark G.R., Denny W.A., Palmer B.D., and Wilson W.R. Synthesis, structures and hypoxia-selective cytotoxicity of cobalt(III) complexes containing tridentate amine and nitrogen mustard ligands. J Chem Soc Dalton Trans (2000) 925-932
25. Craig P.R., Brothers P.J., Clarke G.R., Wilson W.R., Denny W.A., and Ware D.C. Anionic carbonato and oxalato cobalt(III) nitrogen mustard complexes. J Chem Soc Dalton Trans (2004) 611-618
26. Perrin L.C., Wilson W.R., Denny W.A., and McFadyen W.D. The design of cobalt(III) complexes of phenazine-1-carboxamides as prointercalators and potential hypoxia-selective cytotoxins. Anticancer Drug Des 14 (1999) 231-241
27. Craig PR. Cobalt(III) and chromium(III) complexes as anticancer drugs. PhD Thesis, The University of Auckland, 1998.
28. Parker L.L., Lacy S.M., Farrugia L.J., Evans C., Robins D.J., O'Hare C.C., et al. A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs. J Med Chem 47 (2004) 5683-5689
29. Wilson W.R., Tercel M., Anderson R.F., and Denny W.A. Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts. Anticancer Drug Des 13 (1998) 663-685
30. Kriste A.G., Tercel M., Anderson R.F., Ferry D.M., and Wilson W.R. Pathways of reductive fragmentation of heterocyclic nitroarylmethyl quaternary ammonium prodrugs of mechlorethamine. Radiat Res 158 (2002) 753-762
31. Nishimoto S.I., Hatta H., Ureshima H., and Kagiya T. 1-(5′-fluoro-6′-hydroxy-5′,6′-dihydrouracil-5′-yl)-5-fluorouracil, a novel N(1)-C(5)-linked dimer that releases 5-fluorouracil by radiation activation under hypoxic conditions. J Med Chem 35 (1992) 2711-2712
32. Shibamoto Y., Tachi Y., Tanabe K., Hatta H., and Nishimoto S.I. In vitro and in vivo evaluation of novel antitumor prodrugs of 5-fluoro-2′-deoxyuridine activated by hypoxic irradiation. Int J Radiat Oncol Biol Phys 58 (2004) 397-402
33. Tanabe K., Makimura Y., Imagawa-Sato A., and Nishimoto S. Hypoxia-selective activation of 5-fluorodeoxyuridine prodrug possessing indolequinone structure: radiolytic reduction and cytotoxicity characteristics. Bioorg Med Chem Lett 15 (2005) 2321-2324
34. Lee A.E., and Wilson W.R. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol Appl Pharmacol 163 (2000) 50-59
35. Hicks K.O., Pruijn F.B., Sturman J.R., Denny W.A., and Wilson W.R. Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. Cancer Res 63 (2003) 5970-5977
36. Pruijn F.B., Sturman J.R., Liyanage H.D.S., Hicks K.O., Hay M.P., and Wilson W.R. Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogs in multicellular layer cultures. J Med Chem 48 (2005) 1079-1087
37. Ahn G.-O., Ware D.C., Denny W.A., and Wilson W.R. Optimization of the auxiliary ligand shell of Cobalt(III)(8-hydroxyquinoline) complexes as model hypoxia-selective radiation-activated prodrugs. Radiat Res 162 (2004) 315-325
38. Hanka L.J., Dietz A., Gerpheide S.A., Kuentzel S.L., and Martin D.G. CC-1065 (NSC-298223), a new antitumor antibiotic. Production, in vitro biological activity, microbiological assays and taxonomy of the producing microorganism. J Antibiot 31 (1978) 1211-1217
39. Ichimura M., Ogawa T., Takahashi K., Kobayashi E., Kawamoto I., Yasuzawa T., et al. Duocarmycin SA, a new antitumor antibiotic from Streptomyces sp. J Antibiot 43 (1990) 1037-1038
40. Boger D.L., and Johnson D.S. CC-1065 and the duocarmycins: understanding their biological function through mechanistic studies. Angew Chem Int Ed Engl 35 (1996) 1438-1474
41. Boger D.L., and Boyce C.W. Selective metal cation activation of a DNA alkylating agent: synthesis and evaluation of methyl 1,2,9,9a-tetrahydrocycloprop[c]pyrido[3,2-e]indol-4-one-7-carboxylate (CPyI). J Org Chem 65 (2000) 4088-4100
42. Denny WA, Wilson WR, Ware DC, Atwell GJ, Mibank JBJ, Stevenson RJ. Anti-cancer 2,3-dihydro-1H-pyrrolo[3,2-f]quinoline complexes of cobalt and chromium. PCT Patent Application WO02059122A1, 2002.
43. Fricke H., and Hart E.J. Chemical dosimetry. In: Attix F.H., and Roesch W.C. (Eds). Radiation dosimetry vol. 2 (1966), Academic Press, New York 167-239
44. Sykes B.M., Atwell G.J., Hogg A., Wilson W.R., O'Connor C.J., and Denny W.A. N-Substituted 2-(2,6-dinitrophenylamino)propanamides: novel prodrugs that release a primary amine via nitroreduction and intramolecular cyclization. J Med Chem 42 (1999) 346-355
45. Hobbs S., Jitrapakdee S., and Wallace J.C. Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochem Biophys Res Commun 252 (1998) 368-372
46. Patterson A.V., Saunders M.P., Chinje E.C., Talbot D.C., Harris A.L., and Stratford I.J. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU. Br J Cancer 76 (1997) 1338-1347
47. Cowen R.L., Patterson A.V., Telfer B.A., Airley R., Hobbs S., Phillips R.M., et al. Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of Mitomycin C in human breast cancer xenografts. Mol Cancer Ther 2 (2003) 901-909
48. Patterson A.V., Barham H.M., Chinje E.C., Adams G.E., Harris A.L., and Stratford I.J. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer 72 (1995) 1144-1150
49. Buxton G.V. Radiation chemistry of the liquid state: (1) water and homogeneous aqueous solutions. In: Farhataziz, and Rodgers M.A.J. (Eds). Radiation chemistry: principles and applications (1987), VCH Publishers, New York 321-349
50. Mulazzani Q.G., D'Angelantonio M., Venturi M., Hoffman M.Z., and Rodgers M.A.J. Interaction of formate and ozalate ions with radiation-generated radicals in aqueous solution. Methylviologen as a mechanistic probe. J Phys Chem 90 (1986) 5347-5352
51. Gutierrez A., Grunau A., Paine M., Munro A.W., Wolf C.R., Roberts G.C., et al. Electron transfer in human cytochrome P450 reductase. Biochem Soc Trans 31 (2003) 497-501
52. Kriste A.G., Tercel M., Stribbling S.M., Botting K.J., and Wilson W.R. Radiation-activated prodrugs: hypoxia-selective radiolytic release of potent chloromethylbenzindoline (CBI) cytotoxins from novel nitroarylmethyl quaternary (NMQ) prodrugs. Br J Cancer 86 Suppl. 1 (2002) S30-S31
53. Atwell G.J., Tercel M., Boyd M., Wilson W.R., and Denny W.A. Synthesis and cytotoxicity of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2-dihydro-3H-benz[e]indole (amino-seco-CBI-TMI) and related 5-alkylamino analogues: new DNA minor groove alkylating agents. J Org Chem 63 (1998) 9414-9420
54. Atwell G.J., Milbank J.J., Wilson W.R., Hogg A., and Denny W.A. 5-Amino-1-(chloromethyl)-1,2-dihydro-3H-benz[e]indoles: relationships between structure and cytotoxicity for analogues bearing different DNA minor groove binding subunits. J Med Chem 42 (1999) 3400-3411
55. Franklin T.J., Jacobs V.N., Jones G., and Ple P. Human corelectal carcinoma cells in vitro as a means to assess the metabolism of analogs of mycophenolic acid. Drug Metab Dispos 25 (1997) 367-370
56. Monson T.P., Henle K.J., Nagle W.A., and Mansouri A. Tumor-targeted delivery of 8-hydroxyquinoline. Int J Radiat Oncol Biol Phys 20 (1991) 1263-1271
57. Tietze L.F., Lieb M., Herzig T., Haunert F., and Schuberth I. A strategy for tumor-selective chemotherapy by enzymatic liberation of seco-duocarmycin SA-derivatives from nontoxic prodrugs. Bioorg Med Chem 9 (2001) 1929-1939
58. Ichimura M., Ogawa T., Takahashi K., Takahashi I., and Nakano H. Interconversion and stability of duocarmycins, a new family of antitumor antibiotics: correlation to their cytotoxic and antimicrobial activities in vitro. Oncol Res 5 (1993) 165-171
59. Wardman P. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr Med Chem 8 (2001) 739-761